⚡ Flash Summary

LIVEN Pharma Limited announced that unpaid rights shares from their rights issue on September 12, 2025, have been credited into the respective accounts within the Central Depository System (CDS) as of November 28, 2025. This confirms that investors who were entitled to rights shares but had not yet paid for them now have those rights reflected in their CDS accounts. The announcement was made on December 1, 2025, referencing a confirmation letter from the Central Depository Company (CDC). This action allows these rights to be traded or exercised by the shareholders.

📌 Key Takeaways

• ✅ LIVEN Pharma credited unpaid rights into CDS accounts.
• 🗓️ Announcement made December 1, 2025.
• 📢 Rights issue announced earlier on September 12, 2025.
• 🏦 Credit occurred on November 28, 2025.
• 📜 CDC confirmation letter: OPS/CA/RI/002 dated December 1, 2025.
• 🔒 Rights now visible in shareholders’ CDS accounts.
• 💼 Shareholders can now trade or exercise these rights.
• 🏢 The announcement references 19,065,357 securities were allotted.
• ℹ️ Further inquiries can be directed to the Central Depository Company.
• ✉️ Communication sent to Pakistan Stock Exchange.

🎯 Investment Thesis

HOLD. This announcement is administrative in nature, indicating that unpaid rights have been credited to shareholder accounts. While this allows shareholders to exercise or trade their rights, it doesn’t change the fundamental investment case for LIVEN Pharma. Without additional financial information, it’s prudent to maintain a HOLD rating. Any change to BUY or SELL would depend on the exercise of rights shares and its impact on earnings and valuation.